Cover Image
Market Research Report

Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II Receptor blocker (ARBs), ACE Inhibitors & Implantable Devices - Heart pumps, ICDs & Biventricular Pacemakers)-Forecast 2019-2024

Published by IndustryARC Product code 422147
Published Content info
Delivery time: 2-3 business days
Back to Top
Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II Receptor blocker (ARBs), ACE Inhibitors & Implantable Devices - Heart pumps, ICDs & Biventricular Pacemakers)-Forecast 2019-2024
Published: December 11, 2018 Content info:

Dilated Cardiomyopathy (DCM) is a condition in which heart's left ventricle, is enlarged and weakened and the ability to pump blood is decreased. The decreased heart function can influence the lungs, liver, and other body systems progressively. It occurs more commonly in male over female and can develop at any age but most common in population between the age group of 20 and 60 years. DCM also leads to frequent blood clots, uneven heartbeats and valve problems. According to American Society for Clinical Investigation, any mutations in genes encoding cytoskeletal proteins or other proteins involved in contraction of myocardial cells accounts for disease in about 25% - 50% of the total affected individuals of Dilated Cardiomyopathy. Other causes include birth defects, drug or alcohol abuse or certain exposure to toxic substances, viral infections of the heart, diabetes, thyroid disorders and heart valve malformations etc.

Two major options used in the treatment of DCM are oral drugs and implantable devices. Oral drugs available are beta blockers, diuretics, digitalis, angiotensin II receptor blocker (ARBs), warfarin and angiotensin-converting enzyme inhibitors (ACE inhibitors). In implantable devices, heart pumps and cardioverter-defibrillators are mainly used.

The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R activities and increased awareness for timely diagnosis.

This report provides information on DCM treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to DCM.

Geographic regions analyzed for this market is divided into four regions i.e. North America, Europe, Asia Pacific and Rest of the World. Due to increase in numbers of heart problems over the years North America and Asia-Pacific are expected to be major markets for DCM. Europe and Row are other prominent markets for the disease.

This report identifies global DCM on the basis of treatment type and regional market as follows:

Dilated Cardiomyopathy treatment market is segmented based on available treatment options. Mainly two treatment options, drugs and implantable devices are in the market

This report is further segmented based on potential markets for DCM. A detailed analysis by region - United States, Europe, Asia-Pacific (APAC) and Rest of the World (RoW), has been provided in this report.

Sample Companies profiled in this report are:

AstraZeneca plc.

GlaxoSmithKline Int.

Janssen Pharmaceuticals Inc.

Merck & Co. Inc.

Novartis International AG


Table of Contents

Table of Contents

1. Dilated Cardiomyopathy Treatment - Market Overview

2. Executive Summary

3. Dilated Cardiomyopathy Treatment - Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Dilated Cardiomyopathy Treatment - Market Forces

  • 4.1. Drivers
    • 4.1.1. Rise in number of heart failure patients
  • 4.2. Restraints
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Force Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Customers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Dilated Cardiomyopathy Treatment Market - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Dilated Cardiomyopathy Treatment Market

  • 6.1. By type of treatment - Drugs
    • 6.1.1. Beta blockers
    • 6.1.2. Diuretics
    • 6.1.3. Digitalis
    • 6.1.4. Angiotensin II receptor blocker (ARBs)
    • 6.1.5. Angiotensin-converting enzyme inhibitors (ACE inhibitors)
  • 6.2. By type of treatment - Implantable devices
    • 6.2.1. Heart pumps
    • 6.2.2. Cardioverter-defibrillators (ICDs)
    • 6.2.3. Biventricular pacemakers

7. Dilated Cardiomyopathy Treatment Market, By Geography

  • 7.1. Introduction
  • 7.2. America
    • 7.2.1. US
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. Europe
    • 7.3.1. U.K
    • 7.3.2. France
    • 7.3.3. Germany
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe
  • 7.4. Asia Pacific
    • 7.4.1. China
    • 7.4.2. South Korea
    • 7.4.3. Japan
    • 7.4.4. India
    • 7.4.5. Rest of Asia Pacific
  • 7.5. RoW

8. Market Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply - Contract

9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 9.1. GlaxoSmithKline
  • 9.2. Pfizer Inc.
  • 9.3. Novartis A.G
  • 9.4. Merck and Co.
  • 9.5. Janssen Pharmaceuticals
  • 9.6. AstraZeneca plc.
  • 9.7. Array BioPharma, Inc
  • 9.8. Vericel Corporation
  • 9.9. Celladon Corporation
  • 9.10. Teva Pharmaceutical Industries Ltd.

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Sources
  • 10.3. Research Methodology
  • 10.4. Expert Insights
Back to Top